Advertisement

American Journal of Clinical Dermatology

, Volume 8, Issue 3, pp 157–173 | Cite as

The Role of Topical Calcineurin Inhibitors for Skin Diseases Other Than Atopic Dermatitis

  • Uwe Wollina
Review Article

Abstract

The topical calcineurin inhibitors (TCIs) pimecrolimus and tacrolimus are approved for atopic dermatitis but have additional potential in other inflammatory skin diseases. This article reviews their clinical use in non-atopic dermatitis diseases. In seborrheic dermatitis, asteatotic eczema, and contact dermatitis, TCIs are of great benefit and can compete with topical corticosteroids. In psoriasis, TCIs have shown clinical efficacy and safety in facial and intertriginous lesions. Further investigations into possible combinations of TCIs with other established treatments such as UVB irradiation in this disorder are necessary. Initial studies in cutaneous lupus erythematosus have been promising, whereas the response in rosacea and rosacea-like eruptions has been mixed. TCIs have been associated with good clinical responses in oral lichen planus and anogenital lichen sclerosus et atrophicus. In vitiligo, TCIs are associated with some degree of repigmentation, with better results being seen in children and in facial and neck areas. TCIs have a synergistic effect with UVB irradiation in vitiligo. There is a long list of small series and case reports documenting use of TCIs in various other skin conditions that warrant further validation. Although the established mode of action of TCIs is T-cell control, other effects also need to be considered. Specifically, TCIs reduce pruritus and erythema, which cannot be explained by T-cell interactions, and further investigations are needed in these fields.

Keywords

Tacrolimus Atopic Dermatitis Topical Corticosteroid Vitiligo Lichen Planus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

No sources of funding were used to assist in the preparation of this review. The author has received lecturing honoraria from Novartis and Fujisawa.

References

  1. 1.
    Meingassner JG, Aschauer H, Stuetz A. Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin. Exp Dermatol 2005; 14: 752–7PubMedCrossRefGoogle Scholar
  2. 2.
    Paul C, Cork M, Rossi AB. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated up to 2 years. Pediatrics 2006; 117: 118–25CrossRefGoogle Scholar
  3. 3.
    Simpson D, Noble S. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs 2005; 65: 827–58PubMedCrossRefGoogle Scholar
  4. 4.
    Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol 2003; 17: 493–503PubMedCrossRefGoogle Scholar
  5. 5.
    Wolff K, Stuetz A. Pimecrolimus for the treatment of inflammatory skin disease. Expert Opin Pharmacother 2004; 5: 643–55PubMedCrossRefGoogle Scholar
  6. 6.
    Draelos Z, Nayak A, Pariser D. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. J Am Acad Dermatol 2005; 53: 602–9PubMedCrossRefGoogle Scholar
  7. 7.
    Sunderkötter C, Weiss JM, Bextermöller R. Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and quality of life. J Dtsch Dermatol Ges 2006; 4: 301–6PubMedCrossRefGoogle Scholar
  8. 8.
    Rallis E, Nasiopoulou A, Kouskoukis C. Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk. Drugs Exp Clin Res 2004; 30: 191–5PubMedGoogle Scholar
  9. 9.
    Rigopoulos D, Ioannides D, Kalogeromitros D. Pimecrolimus cream 1% vs betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis: a randomized open-label clinical study. Br J Dermatol 2004; 151: 1071–5PubMedCrossRefGoogle Scholar
  10. 10.
    High WA, Pandya AG. Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation. J Am Acad Dermatol 2006; 54: 1083–8PubMedCrossRefGoogle Scholar
  11. 11.
    Warshaw EM, Wohlhuter RJ, Liu A. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol. Epub 2006 Dec 21Google Scholar
  12. 12.
    Firooz A, Solhpour A, Gorouhi F. Pimecrolimus cream, 1%, vs hydrocortisone acetate, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol 2006; 142: 1066–7PubMedGoogle Scholar
  13. 13.
    Sugita T, Tajima M, Tsubuku H. A new calcineurin inhibitor, pimecrolimus, inhibits the growth of Malassezia spp. Antimicrob Agents Chemother 2006; 50: 2897–8PubMedCrossRefGoogle Scholar
  14. 14.
    Braza TJ, DiCarlo JB, Soon SL. Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. Br J Dermatol 2003; 148: 1242–4PubMedCrossRefGoogle Scholar
  15. 15.
    Meshkinpour A, Sun J, Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol 2003; 49: 145–7PubMedCrossRefGoogle Scholar
  16. 16.
    Schulz P, Bunselmeyer B, Bräutigam M. Pimecrolimus cream 1% is effective in asteatotic eczema: results of a randomized, double-blind, vehicle-controlled study in 40 patients. J Eur Acad Dermatol Venereol 2007; 21: 90–4PubMedCrossRefGoogle Scholar
  17. 17.
    Castro AP. Calcineurin inhibitors in the treatment of allergic dermatitis. J Pediatr (Rio J) 2006; 82 Suppl.: 166–72CrossRefGoogle Scholar
  18. 18.
    Queille-Roussel C, Graeber M, Thurston M. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Derm 2000; 42: 349–50PubMedCrossRefGoogle Scholar
  19. 19.
    Belsito D, Wilson DC, Warshaw E. A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. J Am Acad Dermatol 2006; 55: 40–6PubMedCrossRefGoogle Scholar
  20. 20.
    Saripalli YV, Gadzia JE, Belsito DV. Tacrolimus ointment 0.1% in the treatment of nickel-induced allergic contact dermatitis. J Am Acad Dermatol 2003; 49: 477–82PubMedCrossRefGoogle Scholar
  21. 21.
    Pacor ML, Di Lorenzo G, Martinelli N. Tacrolimus ointment in nickel sulphate-induced steroid-resistant allergic contact dermatitis. Allergy Asthma Proc 2006; 27: 527–31PubMedCrossRefGoogle Scholar
  22. 22.
    Alomar A, Puig L, Gallardo CM. Topical tacrolimus 0.1% ointment (Protopic) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1% with greater suppression of late erythema. Contact Derm 2003; 49: 185–8PubMedCrossRefGoogle Scholar
  23. 23.
    Belsito DV, Fowler Jr JF, Marks Jr JG. Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis 2004; 73: 31–8PubMedGoogle Scholar
  24. 24.
    Warshaw EM. Therapeutic options for chronic hand dermatitis. Dermatol Ther 2004; 17: 240–50PubMedCrossRefGoogle Scholar
  25. 25.
    Cohen DE, Heidary N. Treatment of irritant and allergic contact dermatitis. Dermatol Ther 2004; 17: 334–40PubMedCrossRefGoogle Scholar
  26. 26.
    Wollina U, Abdel-Naser MB. Pharmacotherapy of pompholyx. Exp Opin Pharmacother 2004; 5: 1517–22CrossRefGoogle Scholar
  27. 27.
    Bruckner AL, Weston WL. Allergic contact dermatitis in children: a practical approach to management. Skin Therapy Lett 2002; 7: 3–5PubMedGoogle Scholar
  28. 28.
    Schurmeyer-Horst F, Luger TA, Böhm M. Long-term efficacy of occlusive therapy with topical pimecrolimus in severe dyshidrosiform hand and foot eczema. Dermatology 2007; 214: 99–100PubMedCrossRefGoogle Scholar
  29. 29.
    Schnopp C, Remling R, Möhrenschläger M. Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar erythema: a randomized, observer-blinded trial. J Am Acad Dermatol 2002; 46: 73–7PubMedCrossRefGoogle Scholar
  30. 30.
    Kreuter A, Hochdorfer B, Altmeyer P. Pimecrolimus 1% cream for perianal atopic dermatitis. Br J Dermatol 2005; 152: 186–7PubMedCrossRefGoogle Scholar
  31. 31.
    Lazarous MC, Kerdel FA. Topical tacrolimus Protopic. Drugs Today (Barc) 2002; 38: 7–15CrossRefGoogle Scholar
  32. 32.
    Ortonne JP, van de Kerkhof PC, Prinz JC. 0.3% tacrolimus gel and 0.5% tacrolimus cream show efficacy in mild to moderate plaque psoriasis: results of a randomized, open-label, observer-blinded study. Acta Derm Venereol 2006; 86: 29–33PubMedGoogle Scholar
  33. 33.
    Mrowietz U, Graeber M, Bräutigam M. The novel ascomycin derivate SDZ ASM 981 is effective in psoriasis when used topically under occlusion. Br J Dermatol 1998; 139: 992–6PubMedCrossRefGoogle Scholar
  34. 34.
    Griebetz C, Ling M, Lebwohl M. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004; 51: 731–8CrossRefGoogle Scholar
  35. 35.
    Kreuter A, Sommer A, Hyun J. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol 2006; 142: 1138–43PubMedCrossRefGoogle Scholar
  36. 36.
    Lewkowicz D, Gottlieb AB. Pediatric psoriasis and psoriatic arthritis. Dermatol Ther 2004; 17: 364–75PubMedCrossRefGoogle Scholar
  37. 37.
    Freeman AK, Linkowski GJ, Brady C. Tacrolimus ointment for the treatment of psoriasis of the face and intertriginous areas. J Am Acad Dermatol 2003; 48: 564–8PubMedCrossRefGoogle Scholar
  38. 38.
    Rallis E, Nasiopoulou A, Kouskoukis C. Successful treatment of genital and facial psoriasis with tacrolimus ointment 0.1%. Drugs Exp Clin Res 2005; 31: 141–5PubMedGoogle Scholar
  39. 39.
    Martin Ezquerra G, Sanchez Regana M, Herrera Acosta E. Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. J Drugs Dermatol 2006; 5: 334–6Google Scholar
  40. 40.
    Yamamoto T, Nishioka K. Topical tacrolimus: an effective treatment for facial psoriasis. Eur J Dermatol 2003; 13: 471–3PubMedGoogle Scholar
  41. 41.
    Carroll CL, Clarke J, Camacho F. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol 2005; 141: 43–6PubMedCrossRefGoogle Scholar
  42. 42.
    Lebwohl M, Freeman AK, Chapman MS. Tacrolimus is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004; 51: 723–30PubMedCrossRefGoogle Scholar
  43. 43.
    Wilsmann-Theis D, Hagemann T, Dederer H. Successful treatment of acrodermatitis continua suppurativa with topical tacrolimus 0.1% ointment. Br J Dermatol 2004; 150: 1194–7PubMedCrossRefGoogle Scholar
  44. 44.
    Nagao K, Ishiko A, Yokoyama T. A case of generalized pustular psoriasis treated with topical tacrolimus. Arch Dermatol 2003; 139: 1219PubMedGoogle Scholar
  45. 45.
    Brill TJ, Elshorst-Schmidt T, Valesky EM. Successful treatment of acrodermatitis continua of Hallopeau with sequential combination of calcipotriol and tacrolimus ointments. Dermatology 2005; 211: 351–5PubMedCrossRefGoogle Scholar
  46. 46.
    Rodríguez García F, Fagundo Gonzí1lez E, Cabrera-Paz R. Generalized pustular psoriasis successfully treated with topical tacrolimus. Br J Dermatol 2005; 152: 587–8CrossRefGoogle Scholar
  47. 47.
    Rivard J, Janiga J, Lim HW. Tacrolimus ointment 0.1% alone and in combination with medium-dose UVA1 in the treatment of palmar or plantar psoriasis. J Drugs Dermatol 2006; 5: 505–10PubMedGoogle Scholar
  48. 48.
    Afifi T, de Gannes G, Huang C. Topical therapies for psoriasis: evidence-based review. Can Fam Physician 2005 Apr; 51: 519–25PubMedGoogle Scholar
  49. 49.
    Tan JKL, Morneau K, Fung K. Randomized controlled trial of pimecrolimus 1% cream for treatment of facial acne vulgaris. J Am Acad Dermatol 2005; 52: 738–9PubMedCrossRefGoogle Scholar
  50. 50.
    Barr J, Friedman A. Use of imiquimod and pimecrolimus cream in the treatment of acne keloidalis nuchae [abstract]. J Am Acad Dermatol 2005; 52: 64CrossRefGoogle Scholar
  51. 51.
    Crawford KM, Russ B, Bostrom P. Pimecrolimus for treatment of acne rosacea. Skinmed 2005; 4: 147–50PubMedCrossRefGoogle Scholar
  52. 52.
    Chu C-Y. The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. Br J Dermatol 2005; 152: 396–9PubMedCrossRefGoogle Scholar
  53. 53.
    Meykadeh N, Meiss F, Marsch WC. Steroid-aggravated rosacea: successful therapy with pimecrolimus [in German]. Hautarzt 2007 Apr; 58 (4): 338–42PubMedCrossRefGoogle Scholar
  54. 54.
    Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol 2001; 44: 995–8PubMedCrossRefGoogle Scholar
  55. 55.
    Pabby A, An KP, Laws RA. Combination therapy of tetracycline and tacrolimus resulting in rapid resolution of steroid-induced periocular rosacea. Cutis 2003; 72: 141–2PubMedGoogle Scholar
  56. 56.
    Gorman CR, White SW. Rosaceiform dermatitis as a complication of treatment of facial seborrheic dermatitis with 1% pimecrolimus cream [letter]. Arch Dermatol 2005; 141: 1168PubMedCrossRefGoogle Scholar
  57. 57.
    Bernard LA, Cunningham BB, Al-Suwaidan S. A rosacea-like granulomatous eruption in a patient using tacrolimus ointment for atopic dermatitis. Arch Dermatol 2003; 139: 229–31PubMedGoogle Scholar
  58. 58.
    El Sayed F, Ammoury A, Dhaybi R. Rosaceiform eruption to pimecrolimus. J Am Acad Dermatol 2006; 54: 548–50PubMedCrossRefGoogle Scholar
  59. 59.
    Tlaculio-Parra A, Guevara-Gutierrez E, Gutierrez-Murillo F. Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology (Oxford) 2005; 44: 1564–8CrossRefGoogle Scholar
  60. 60.
    Kreuter A, Gambichler T, Breuckmann F. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004; 51: 407–10PubMedCrossRefGoogle Scholar
  61. 61.
    Lampropoulos CE, Sangle S, Harrison P. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology 2004; 43: 1383–5PubMedCrossRefGoogle Scholar
  62. 62.
    Sugano M, Shitani Y, Kobayashi K. Successful treatment with topical tacrolimus in four cases of discoid lupus erythematosus. J Dermatol 2006; 33: 887–9PubMedCrossRefGoogle Scholar
  63. 63.
    Yoshimasu T, Ohtani T, Sakamoto T. Topical FK 506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatofor myositis. Eur J Dermatol 2002; 12: 50–2PubMedGoogle Scholar
  64. 64.
    Böhm M, Gaubitz M, Luger TA. Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus: a report of three cases. Dermatology 2003; 207: 381–5PubMedCrossRefGoogle Scholar
  65. 65.
    Von Pelchrzim R, Schmook T, Friedrich M. Efficacy of topical tacrolimus in the treatment of various cutaneous manifestations of lupus erythematosus. Int J Dermatol 2006; 45: 84–5CrossRefGoogle Scholar
  66. 66.
    Kanekura T, Yoshii N, Terasaki K. Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br J Dermatol 2003; 148: 353–6PubMedCrossRefGoogle Scholar
  67. 67.
    Rubegni P, Sbano P, Risulo M. A case of reticular erythematous mucinosis treated with topical tacrolimus. Br J Dermatol 2004; 150: 173–4PubMedCrossRefGoogle Scholar
  68. 68.
    Tzung T-Y, Wu J-C. Topical calcineurin inhibitors in treating Jessner’s lymphocytic infiltration of the skin: report of a case. Br J Dermatol 2005; 152: 383–4PubMedCrossRefGoogle Scholar
  69. 69.
    Peyrot I, Sparsa A, Loustad-Ratti V. Topical tacrolimus and resistant lesions of dermatomyositis. Rev Med Interne 2006; 27: 730–5PubMedCrossRefGoogle Scholar
  70. 70.
    Ueda M, Makinodan R, Matsumara M. Successful treatment of amyopathic dermatomyositis with topical tacrolimus. Br J Dermatol 2003; 148: 595–6PubMedCrossRefGoogle Scholar
  71. 71.
    Lampropoulos CE, D’Cruz DP. Topical tacrolimus treatment in a patient with dermatomyositis. Ann Rheum Dis 2005; 64: 1376–7PubMedCrossRefGoogle Scholar
  72. 72.
    Garcia-Doval I, Cruses M. Topical tacrolimus in cutaneous lesions of dermatomyositis: lack of effect in side-by-side comparison in five patients. Dermatology 2004; 209: 247–8PubMedCrossRefGoogle Scholar
  73. 73.
    Manusco G, Berdondini RM. Topical tacrolimus in the treatment of localized scleroderma. Eur J Dermatol 2003; 13: 590–2Google Scholar
  74. 74.
    Santos-Juanes J, Sanchez del Rio J, Galache C. Topical tacrolimus: an effective therapy for Zoon balanitis. Arch Dermatol 2004; 140: 1538–9PubMedCrossRefGoogle Scholar
  75. 75.
    Hernandez-Machin B, Borrego Hernando L, Báez Marrero O. Plasma cell balanitis of Zoon treated successfully with topical tacrolimus. Clin Exp Dermatol 2005; 30: 588–9PubMedCrossRefGoogle Scholar
  76. 76.
    De Almeida HL, de Oliveira Filho UL. Topical pimecrolimus is an effective treatment for balanitis circinata erosiva. Int J Dermatol 2005; 44: 888–9PubMedCrossRefGoogle Scholar
  77. 77.
    Moreno-Arias GA, Camps-Fresneda A, Llaberia C. Plasma cell balanitis treated with tacrolimus 0.1%. Br J Dermatol 2005; 153: 1204–6PubMedCrossRefGoogle Scholar
  78. 78.
    Roé E, Dalmau J, Peramiquel L. Plasma cell balanitis of Zoon treated with topical tacrolimus 0.1%; report of three cases. J Eur Acad Dermatol Venereol 2007; 21: 284–5PubMedGoogle Scholar
  79. 79.
    Almeida Jr HL, Oliveira Filho UL. Topical pimecrolimus is an effective treatment for balanitis circinata erosive. Int J Dermatol 2005; 44: 888–9PubMedCrossRefGoogle Scholar
  80. 80.
    Davatchi F. New and innovative therapies for Behcet’s disease. APLAR J Rheumatol 2004; 7: 141–5CrossRefGoogle Scholar
  81. 81.
    Lin P, Liang G. Behcet disease: recommendation for clinical management of mucocutaneous lesions. J Clin Rheumatol 2006; 12: 282–6PubMedCrossRefGoogle Scholar
  82. 82.
    Lim SJ, Love EW. Steroid-free pimecrolimus (Elidel) for monotherapy of lichen planus. J Drugs Dermatol 2004; 3: 563–4PubMedGoogle Scholar
  83. 83.
    Lonsdale-Eccles AA, Velangi S. Topical pimecrolimus in the treatment of genital lichen planus: a prospective case series. Br J Dermatol 2005; 153: 390–4PubMedCrossRefGoogle Scholar
  84. 84.
    Byrd JA, Davis MDP, Rogers III RS. Recalcitrant symptomatic vulvar lichen planus: response to topical tacrolimus. Arch Dermatol 2004; 140: 715–20PubMedCrossRefGoogle Scholar
  85. 85.
    Jensen JT, Bird M, Leclair CM. Patient satisfaction after the treatment of vulvovaginal erosive lichen planus with topical clobetasol and tacrolimus: a survey study. Am J Obstet Gynecol 2004; 190: 1759–63PubMedCrossRefGoogle Scholar
  86. 86.
    Kaliakatsou F, Hodgson TA, Lewsey JD. Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus. J Am Acad Dermatol 2002; 46: 35–41PubMedCrossRefGoogle Scholar
  87. 87.
    Rozycki TW, Rogers III RS, Pittelkow MR. Topical tacrolimus in the treatment of symptomatic oral lichen planus: a series of 13 patients. J Am Acad Dermatol 2002; 46: 27–34PubMedCrossRefGoogle Scholar
  88. 88.
    Morrison L, Kratochvil III FJ, Gorman A. An open trial of topical tacrolimus for erosive oral lichen planus. J Am Acad Dermatol 2002; 47: 617–20PubMedCrossRefGoogle Scholar
  89. 89.
    Thomson MA, Hamburger J, Stewart DG. Treatment of erosive oral lichen planus with topical tacrolimus. J Dermatolog Treat 2004; 15: 308–15PubMedCrossRefGoogle Scholar
  90. 90.
    Byrd JA, Davis MD, Bruce AJ. Response of oral lichen planus to topical tacrolimus in 37 patients. Arch Dermatol 2004; 140: 1508–12PubMedCrossRefGoogle Scholar
  91. 91.
    Scheer M, Kawari-Mahmoodi N, Neugebauer J. Pimecrolimus (Elidel®) for therapy of lichen ruber mucosae. deMund Kiefer Gesichtschir 2006; 10: 403–7CrossRefGoogle Scholar
  92. 92.
    Esquivel-Pedraza L, Fernández-Cuevas L, Ortíz-Pedroza G. Treatment of oral lichen planus with topical pimecrolimus 1% cream. Br J Dermatol 2004; 150: 771–3PubMedCrossRefGoogle Scholar
  93. 93.
    Laeijendecker R, Tank B, Dekker SK. A comparison of treatment of oral lichen planus with topical tacrolimus and triamcinolone acetonide ointment. Acta Derm Venereol 2006; 86: 227–9PubMedCrossRefGoogle Scholar
  94. 94.
    Mattsson U, Jontell M, Holmstrup P. Oral lichen planus and malignant transformation: is a recall of patients justified? Crit Rev Oral Biol Med 2002; 13: 390–6PubMedCrossRefGoogle Scholar
  95. 95.
    Ring J, Barker J, Behrendt H. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol 2005; 19: 663–71PubMedCrossRefGoogle Scholar
  96. 96.
    Berger TG, Duvic M, Van Voorhees AS. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006; 54: 818–23Google Scholar
  97. 97.
    Simpkin S, Oakley A. Clinical review of 202 patients with vulval lichen sclerosus: a possible association with psoriasis. Australas J Dermatol 2007 Feb; 48 (1): 28–31PubMedCrossRefGoogle Scholar
  98. 98.
    Goldstein AT, Marinoff SC, Christopher K. Pimecrolimus for the treatment of vulvar lichen sclerosus: a report of 4 cases. J Reprod Med 2004; 49: 778–80PubMedGoogle Scholar
  99. 99.
    Nissi R, Eriksen H, Risteli J. Pimecrolimus cream 1% in the treatment of lichen sclerosus. Gynecol Obstet Invest 2006; 63: 151–4PubMedCrossRefGoogle Scholar
  100. 100.
    Virgili A, Lauriola MM, Mantovani L. Vulvar lichen sclerosus: 11 women treated with tacrolimus 0.1% ointment. Acta Derm Venereol 2007; 87: 69–72PubMedCrossRefGoogle Scholar
  101. 101.
    Hengge U, Krause W, Hofman H. Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus. Br J Dermatol 2006; 155: 1021–8PubMedCrossRefGoogle Scholar
  102. 102.
    Boms S, Gambichler T, Freitag M. Pimecrolimus 1% cream for anogenital lichen sclerosus in childhood. BMC Dermatol 2004; 4: 14PubMedCrossRefGoogle Scholar
  103. 103.
    Goldstein AT, Marinoff SC, Christopher K. Pimecrolimus for the treatment of vulvar lichen sclerosus in a premenarchal girl. J Pediatr Adolesc Gynecol 2004; 17: 35–7PubMedCrossRefGoogle Scholar
  104. 104.
    Matsumoto Y, Yamamoto T, Isobe T. Successful treatment of vulvar lichen sclerosus in a child with low-concentration topical tacrolimus ointment. J Dermatol 2007; 34: 114–6PubMedCrossRefGoogle Scholar
  105. 105.
    Aricano O, Ciralik H, Sasmaz S. Unsuccessful treatment of extragenital lichen sclerosus with topical 1% pimecrolimus cream. J Dermatol 2004; 31: 1014–7Google Scholar
  106. 106.
    Grimes PE. New insights and new therapies in vitiligo. JAMA 2005; 293: 730–5PubMedCrossRefGoogle Scholar
  107. 107.
    Coskun B, Saral Y, Turgut D. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol 2005; 15: 88–91PubMedGoogle Scholar
  108. 108.
    Dawid M, Veensalu M, Grassberger M. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized double-blind, vehicle-controlled study. J Dtsch Dermatol Ges 2006; 4: 942–6PubMedCrossRefGoogle Scholar
  109. 109.
    Boone B, Onganae K, Van Geel N. Topical pimecrolimus in the treatment of vitiligo. Eur J Dermatol 2007; 17: 55–61PubMedGoogle Scholar
  110. 110.
    Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 47: 789–91PubMedCrossRefGoogle Scholar
  111. 111.
    Tanghetti EA. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis 2003; 71: 158–62PubMedGoogle Scholar
  112. 112.
    Lepe V, Moncada B, Castanedo-Cazares JP. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581–5PubMedCrossRefGoogle Scholar
  113. 113.
    Kanwar AJ, Dogra S, Parsad D. Topical tacrolimus for treatment of childhoodvitiligo in Asians. Clin Exp Dermatol 2004; 29: 589–92PubMedCrossRefGoogle Scholar
  114. 114.
    Almeida P, Borrego L, Rodriguez-Lopez J. Vitiligo: treatment of 12 cases with topical tacrolimus. Actas Dermatosifiliogr 2005; 96: 159–63CrossRefGoogle Scholar
  115. 115.
    Passeron T, Ostovari N, Zakaria W. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004; 140: 1065–9PubMedCrossRefGoogle Scholar
  116. 116.
    Ostovari N, Passeron T, Lacour JP. Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. Arch Dermatol 2006; 142: 252–3PubMedCrossRefGoogle Scholar
  117. 117.
    Oji V, Beljan G, Beiner K. Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. Br J Dermatol 2005; 153: 1067–8PubMedCrossRefGoogle Scholar
  118. 118.
    Thaci D, Pätzold S, Schwanner S. Comel-Netherton syndrome: a case treated with topical pimecrolimus cream 1%. J Eur Acad Dermatol Venereol 2004; 18 Suppl. 2: 160–1Google Scholar
  119. 119.
    Sun JD, Linden KG. Netherton syndrome: a case report and review of the literature. Int J Dermatol 2005; 45: 693–7CrossRefGoogle Scholar
  120. 120.
    Allen A, Siegfried E, Silverman R. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001; 137: 747–50PubMedGoogle Scholar
  121. 121.
    Bens G, Boralevi F, Buenet C. Topical treatment of Netherton’s syndrome with tacrolimus ointment without significant systemic absorption. Br J Dermatol 2003; 149: 224–5PubMedCrossRefGoogle Scholar
  122. 122.
    Saif GB, Al-Kenaizan S. Netherton syndrome: successful use of topical tacrolimus and pimecrolimus in four siblings. Int J Dermatol 2006; 46: 290–4CrossRefGoogle Scholar
  123. 123.
    Bienemann K, Gudowius S, Niehues T. Topical tacrolimus is effective against eczema in Wiskott-Aldrich syndrome (WAS). Acta Paediatr 2007; 96: 312–4PubMedCrossRefGoogle Scholar
  124. 124.
    Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol 2002; 2: 149–58CrossRefGoogle Scholar
  125. 125.
    Lyon CC, Smith AJ, Beck MH. Parastomal pyoderma gangrenosum: clinical features and management. J Am Acad Dermatol 2000; 42: 992–1002PubMedCrossRefGoogle Scholar
  126. 126.
    Khurrum Baig M, Marquez H, Nogueras JJ. Topical tacrolimus (FK506) in the treatment of parastomal pyoderma gangrenosum associated with Crohn’s disease: report of two cases. Colorectal Dis 2004; 6: 250–3CrossRefGoogle Scholar
  127. 127.
    Chiba T, Isomura I, Suzuki A. Topical tacrolimus therapy for pyoderma gangrenosum. J Dermatol 2005; 32: 199–203PubMedGoogle Scholar
  128. 128.
    Lally A, Hollowood K, Bunker CB. Penile pyoderma gangrenosum treated with topical tacrolimus. Arch Dermatol 2005; 141: 1175–6PubMedCrossRefGoogle Scholar
  129. 129.
    Deckers-Kocken JM, Pasmans SGMA. Successful tacrolimus (FK506) therapy in a child with pyoderma gangrenosum [letter]. Arch Dis Child 2005; 90: 531PubMedCrossRefGoogle Scholar
  130. 130.
    Rabeni EJ, Cunningham NM. Effective treatment of Hailey-Hailey disease with topical tacrolimus. J Am Acad Dermatol 2002; 47: 797–8PubMedCrossRefGoogle Scholar
  131. 131.
    Sand C, Thomsen HK. Topical tacrolimus ointment is an effective therapy for Hailey-Hailey disease. Arch Dermatol 2003; 139: 1401–2PubMedCrossRefGoogle Scholar
  132. 132.
    Umar S, Bhattacharjee P, Brodell RT. Treatment of Hailey-Hailey disease with tacrolimus ointment and clobetasol propionate foam. J Drugs Dermatol 2004; 3: 200–3PubMedGoogle Scholar
  133. 133.
    Reuter J, Termeer C, Bruckner-Tuderman L. Tacrolimus: a new therapeutic option for Hailey-Hailey-disease? J Dtsch Dermatol Ges 2005; 3: 278–9PubMedGoogle Scholar
  134. 134.
    Gach JE, Ilchyshyn A. Beneficial effects of topical tacrolimus on recalcitrant erosions of pemphigus vulgaris. Clin Exp Dermatol 2004; 29: 271–2PubMedCrossRefGoogle Scholar
  135. 135.
    Termeer CC, Techau K, Augustin M. Topical tacrolimus (Protopic) for the treatment of a localized pemphigus foliaceus. J Eur Acad Dermatol Venereol 2004; 18: 636–7PubMedCrossRefGoogle Scholar
  136. 136.
    Cohen SN, Lim RPR, Paul CJ. Equal efficacy of topical tacrolimus and clobetasone butyrate in pemphigus foliaceus [letter]. Int J Dermatol 2006; 45: 1379PubMedCrossRefGoogle Scholar
  137. 137.
    Hall VC, Liesegang TJ, Kostick DA. Ocular mucous membrane pemphigoid and ocular pemphigus vulgaris treated topically with tacrolimus ointment. Arch Dermatol 2003; 139: 1083–4PubMedCrossRefGoogle Scholar
  138. 138.
    Günther C, Wozel G, Meuerer M. Topical tacrolimus treatment for cicatricial pemphigoid. J Am Acad Dermatol 2004; 50: 325–6PubMedCrossRefGoogle Scholar
  139. 139.
    Assmann T, Becker J, Ruzicka T. Topical tacrolimus for oral cicatricial pemphigoid. Clin Exp Dermatol 2004; 29: 674–6PubMedCrossRefGoogle Scholar
  140. 140.
    Suresh L, Martinez Calixto LE, Radfar L. Successful treatment of mucous membrane pemphigoid with tacrolimus. Spec Care Dentist 2006; 26: 66–70PubMedCrossRefGoogle Scholar
  141. 141.
    Wenzel J, Philipp-Dormston W, Bieber T. Topical treatment of bullous pemphigoid with tacrolimus: case report with brief literature review. J Dtsch Dermatol Ges 2005; 3: 207–10PubMedCrossRefGoogle Scholar
  142. 142.
    Schmook T, Kraft J, Benninghoff B. Treatment of cutaneous chronic graft-versus-host disease with topical pimecrolimus. Bone Marrow Transplant 2005; 36: 87–8PubMedCrossRefGoogle Scholar
  143. 143.
    Elad S, Or R, Resnick I. Topical tacrolimus: a novel treatment alternative for cutaneous chronic graft-versus-host disease. Transpl Int 2003; 16: 665–70PubMedGoogle Scholar
  144. 144.
    Heinemann C, Kaatz M, Schreiber G. Topical tacrolimus in severe chronic graft-versus-host disease. Acta Derm Venereol 2005; 85: 370–1PubMedCrossRefGoogle Scholar
  145. 145.
    Ziemer M, Gruhn M, Thiele JJ. Treatment of extensive chronic cutaneous graft-versus-host disease in an infant with topical pimecrolimus. J Am Acad Dermatol 2004; 50: 946–8PubMedCrossRefGoogle Scholar
  146. 146.
    Neuman DL, Farrar JE, Moresi JM. Toxic absorption of tacrolimus in a patient with severe acute graft-versus-host disease. Bone Marrow Transplant 2005; 36: 919–20PubMedCrossRefGoogle Scholar
  147. 147.
    Eckardt A, Starke O, Stadler M. Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus. Oral Oncol 2004; 40: 811–4PubMedCrossRefGoogle Scholar
  148. 148.
    Sanchez AR, Sheridan PJ, Rogers RS. Successful treatment of oral lichen planus-like chronic graft-versus-host disease with topical tacrolimus: a case report. J Periodontol 2004; 75: 613–9PubMedCrossRefGoogle Scholar
  149. 149.
    Casson DH, Eltumi M, Tomlin S. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn’s disease. Gut 2000; 47: 436–40PubMedCrossRefGoogle Scholar
  150. 150.
    Corrocher G, Di Lorenzo G, Mansueto P. Comparison of topical tacrolimus 0.1% in pectin ointment with clobetasol 0.5% ointment in adults with moderate to severe desquamative gingivitis: a 4-week, randomized, double-blind clinical trial. Clin Ther 2006; 28: 1296–302PubMedCrossRefGoogle Scholar
  151. 151.
    Almeida Jr HL. Successful treatment of chronic actinic dermatitis with topical pimecrolimus. Int J Dermatol 2005; vn44: 343–4CrossRefGoogle Scholar
  152. 152.
    Uetsu N, Okamoto H, Fuji K. Treatment of chronic actinic dermatitis with tacrolimus ointment. J Am Acad Dermatol 2002; 47: 881–4PubMedCrossRefGoogle Scholar
  153. 153.
    Ogawa Y, Adachi A, Tomita Y. The successful use of topical tacrolimus treatment for a chronic actinic dermatitis patient with a complication of idiopathic leukopenia. J Dermatol 2003; 30: 805–9PubMedGoogle Scholar
  154. 154.
    Evans AV, Palmer RA, Hawk JL. Erythrodermic chronic actinic dermatitis responding only to topical tacrolimus. Photodermatol Photoimmunol Photomed 2004; 20: 59–61PubMedCrossRefGoogle Scholar
  155. 155.
    Djalilia HR, Memar O. Topical pimecrolimus 1% for the treatment of pruritic external auditory canals. Laryngoscope 2006; 116: 1809–12CrossRefGoogle Scholar
  156. 156.
    Sarifakioglu E, Gumus II. Efficacy of topical pimecrolimus in the treatment of chronic vulvar pruritus: a prospective case series: a non-controlled open-label study. J Dermatolog Treat 2006; 17: 276–8PubMedCrossRefGoogle Scholar
  157. 157.
    Connolly M, Kennedy C. Exfoliative cheilitis successfully treated with topical tacrolimus. Br J Dermatol 2004; 151: 241–2PubMedCrossRefGoogle Scholar
  158. 158.
    Rubegni P, Poggiali S, Risulo M. A case of Darier’s disease successfully treated with topical tacrolimus. J Eur Acad Dermatol Venereol 2005; 20: 84–7CrossRefGoogle Scholar
  159. 159.
    Suga Y, Tsuboi R, Hashimoto Y. A case of ichthyosis linearis circumflexa successfully treated with topical tacrolimus. J Am Acad Dermatol 2000; 42: 520–2PubMedCrossRefGoogle Scholar
  160. 160.
    Simon D, Boudny C, Nievergelt H. Successful treatment of pityriasis lichenoides with topical tacrolimus. Br J Dermatol 2004; 150: 1033–5PubMedCrossRefGoogle Scholar
  161. 161.
    Katoh N, Mihara H, Yasuno H. Cutaneous sarcoidosis successfully treated with topical tacrolimus. Br J Dermatol 2002; 147: 154–6PubMedCrossRefGoogle Scholar
  162. 162.
    Harth W, Linse R. Topical tacrolimus in granuloma annulare and necrobiosis lipoidica. Br J Dermatol 2004; 150: 792–4PubMedCrossRefGoogle Scholar
  163. 163.
    Castanedo-Cazares JP, Lepe V, Moncada B. Lichen amyloidosis improved by 0.1% topical tacrolimus. Dermatology 2002; 205: 420–1PubMedCrossRefGoogle Scholar
  164. 164.
    Marcoval J, Moreno A, Bordas X. Granuloma faciale: treatment with topical tacrolimus. J Am Acad Dermatol 2006; 55 Suppl.: 110–1CrossRefGoogle Scholar
  165. 165.
    Hara D, Kuroda K, Mieno H. Treatment of eosinophilic pustular folliculitis with tacrolimus ointment. J Am Acad Dermatol 2004; 51 Suppl.: 143–5CrossRefGoogle Scholar
  166. 166.
    Sáez M, Rodríguez-Martín M, Sidro M. Successful treatment of erosive pustular dermatosis of the scalp with topical tacrolimus. Clin Exp Dermatol 2005; 30: 578–602CrossRefGoogle Scholar
  167. 167.
    Rho NK, Kim BJ. Eosinophilic pustular folliculitis: successful treatment with topical pimecrolimus. Clin Exp Dermatol 2006; 32: 108–9Google Scholar
  168. 168.
    Laffitte E, Kaya G, Piguet V. Erosive pustular dermatosis of the scalp: treatment with topical tacrolimus. Arch Dermatol 2003; 139: 712–4PubMedCrossRefGoogle Scholar
  169. 169.
    Brouard MC, Prins C, Chavaz P. Erosive pustular dermatosis of the leg: report of three cases. Br J Dermatol 2002; 147: 765–9PubMedCrossRefGoogle Scholar
  170. 170.
    Mutasim DF. Successful treatment of inflammatory linear verrucous epidermal nevus with tacrolimus and fluocinonide. J Cutan Med Surg 2006; 10: 45–7PubMedGoogle Scholar
  171. 171.
    El-Dars LD, Statham BN, Blackford S. Lymphocytoma cutis treated with topical tacrolimus. Clin Exp Dermatol 2005; 30: 305–7PubMedCrossRefGoogle Scholar
  172. 172.
    Rallis E, Economidi A, Verros C. Successful treatment of patch type mycosis fungoides with tacrolimus ointment 0.1%. J Drugs Dermatol 2006; 5: 906–7PubMedGoogle Scholar
  173. 173.
    Mackelfresh J, Soon S, Arbiser JL. Combination of doxycycline and topical tacrolimus for venous ulcers. Arch Dermatol 2005; 141: 1476–7PubMedCrossRefGoogle Scholar
  174. 174.
    Campbell FA, Gupta G. Lichenoid tattoo reaction responding to topical tacrolimus ointment. Clin Exp Dermatol 2005; 31: 293–4CrossRefGoogle Scholar
  175. 175.
    Mercader P, de la Cuadra-Oyanguren J, Rodriguez-Serna M. Treatment of protein contact dermatitis with topical tacrolimus. Acta Derm Venereol 2005; 85 (6): 555–6PubMedGoogle Scholar
  176. 176.
    Moody BR, Sengelmann RD. Topical tacrolimus in the treatment of bovine collagen hypersensitivity. Dermatol Surg 2001; 27: 789–91PubMedCrossRefGoogle Scholar
  177. 177.
    Shipley DR, Kennedy CTC. Juvenile plantar dermatosis responding to topical tacrolimus ointment. Clin Exp Dermatol 2006; 31: 453–4PubMedCrossRefGoogle Scholar
  178. 178.
    Edmonds EVJ, Riaz SN, Francis N. Nodular prurigo responding to topical tacrolimus. Br J Dermatol 2004; 150: 1216–7PubMedCrossRefGoogle Scholar
  179. 179.
    Rodriguez-Martin M, Saez-Rodriguez M, Carnerero-Rodriguez A. Treatment of perioral dermatitis with topical pimecrolimus. J Am Acad Dermatol 2007; 56: 529–30PubMedCrossRefGoogle Scholar
  180. 180.
    Aguilar-Bernier M, Bassas-Vila J, Sanz-Munoz C. Successful treatment of pruritus with topical tacrolimus in a patient with primary biliary cirrhosis. Br J Dermatol 2005; 152: 803–9CrossRefGoogle Scholar
  181. 181.
    Lee HW, Jeong YI, Choi JC. Two cases of telangiectasia macularis eruptiva perstans demonstrated by immunohistochemistry for c-kit (CD 117). J Dermatol 2005; 32: 817–20PubMedGoogle Scholar
  182. 182.
    Almeida Jr HL. Treatment of steroid-resistant nodular scabies with topical pimecrolimus. J Am Acad Dermatol 2005; 53: 357–8PubMedCrossRefGoogle Scholar
  183. 183.
    Suli DJ, Harford R, O’Neill JT. Discrete popular form of lichen myxedematosus: a case report and review of the literature. Cutis 2005; 75: 105–12Google Scholar
  184. 184.
    Böhm M, Bonsmann G, Luger TA. Resolution of lichen aureus in a 10-year-old child after topical pimecrolimus. Br J Dermatol 2004; 150: 519–20CrossRefGoogle Scholar
  185. 185.
    Rigopoulos D, Prantsidis A, Christofidou E. Pimecrolimus 1% cream in the treatment of disseminated granuloma annulare. Br J Dermatol 2005; 152: 1364–5PubMedCrossRefGoogle Scholar
  186. 186.
    Eetam I, Ertekin B, Unal I. Granuloma faciale: is it a new indication for pimecrolimus? J Dermatolog Treat 2006; 17: 238–40PubMedCrossRefGoogle Scholar
  187. 187.
    Hafner C, Hohenleutner U, Babilas P. Targeting T cells to hit B cells: successful treatment of cutaneous plasmacytosis with topical pimecrolimus. Dermatology 2006; 213: 163–5PubMedCrossRefGoogle Scholar
  188. 188.
    Kus S, Ince U. Lichen striatus in an adult patient treated with pimecrolimus. J Eur Acad Dermatol Venereol 2006; 20: 341–62CrossRefGoogle Scholar
  189. 189.
    Pock L, Svrcková M, Machácková R. Pimecrolimus is effective in Fox-Fordyce disease. Int J Dermatol 2006; 45: 1134–5PubMedCrossRefGoogle Scholar
  190. 190.
    FDA.FDA Public Health Advisory: January 19, 2006 [online]. Available from URL: http://www.fda.gov./bbs/topics/news/2006/NEW1299.html [Accessed 2006 Sep 30
  191. 191.
    Saitta P, Brancaccio R. Allergic contact dermatitis to pimecrolimus. Contact Derm 2007; 56: 43–4PubMedCrossRefGoogle Scholar
  192. 192.
    Shaw DW, Maibach HI, Eichenfield LF. Allergic contact dermatitis from pimecrolimus in a patient with tacrolimus allergy. J Am Acad Dermatol 2007; 56: 342–5PubMedCrossRefGoogle Scholar
  193. 193.
    Andersen KE, Broesby-Olsen S. Allergic contact dermatitis from oleyl alcohol in Elidel® cream. Contact Derm 2006; 55: 354–6PubMedCrossRefGoogle Scholar
  194. 194.
    Lübbe J, Sanchez-Plitta S. Propolis, beeswax, and the sensitization potential of topical calcineurin inhibitors. Clin Exp Dermatol 2005; 31: 147–8CrossRefGoogle Scholar
  195. 195.
    Knight AK, Boxer M, Chandler MJ. Alcohol-induced rash caused by topical tacrolimus. Ann Allergy Asthma Immunol 2005; 95: 291–2PubMedCrossRefGoogle Scholar
  196. 196.
    Milingou M, Antille C, Sorg O. Alcohol intolerance and facial flushing in patients treated with topical tacrolimus. Arch Dermatol 2004; 140: 1522–4CrossRefGoogle Scholar
  197. 197.
    Sackett DL, Rosenberg WM. The need for evidence-based medicine. J R Soc Med 1995; 88: 620–4PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Department of Dermatology and AllergologyAcademic Teaching Hospital of the Technical University of DresdenDresdenGermany

Personalised recommendations